Risk assessment of tuberculosis in immunocompromised patients: A TBNET study

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 10, 2014, Pages 1168-1176

  Sester, Martina ^a   Van Leth, Frank ^b   Bruchfeld, Judith ^c   Bumbacea, Dragos ^d   Cirillo, Daniela M ^e   Dilektasli, Asli Gorek ^f,w   Domínguez, José ^g   Duarte, Raquel ^h   Ernst, Martin ⁱ   Eyuboglu, Fusun Oner ^f   Gerogianni, Irini ^j   Girardi, Enrico ^k   Goletti, Delia ^k   Janssens, Jean Paul ^l   Julander, Inger ^c   Lange, Berit ^m   Latorre, Irene ^g,x   Losi, Monica ^n,y   Markova, Roumiana ^o   Matteelli, Alberto ^p   Milburn, Heather ^q   Ravn, Pernille ^r   Scholman, Theresia ^a   Soccal, Paola M ^l   Straub, Marina ^m   Wagner, Dirk ^m   Wolf, Timo ^s   Yalcin, Aslihan ^t,z   Lange, Christoph ^c,i,u,v   TBNET, ^aa   more..

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f BASKENT UNIVERSITY   (Turkey)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h University of Porto   (Portugal)

ⁱ RESEARCH CENTER BORSTEL   (Germany)

^j UNIVERSITY OF THESSALY   (Greece)

^k NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^l GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^m UNIVERSITY OF FREIBURG   (Germany)

ⁿ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^o NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

^p UNIVERSITY OF BRESCIA   (Italy)

^q UNIVERSITY OF LONDON   (United Kingdom)

^r HILLERØD HOSPITAL   (Denmark)

^s GOETHE UNIVERSITY   (Germany)

^t ANKARA UNIVERSITY   (Turkey)

^u UNIVERSITY OF LÜBECK   (Germany)

^v UNIVERSITY OF NAMIBIA   (Namibia)

^w ULUDAG UNIVERSITY   (Turkey)

^x UNIVERSITAT POMPEU FABRA   (Spain)

^y UNIVERSITY OF ROME TOR VERGATA   (Italy)

^z MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^aa NONE

more..

Author keywords

Immunocompromised; Interferon release assays; TBNET; Tuberculin skin test; Tuberculosis

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS TEST KIT; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SELF REPORT; STEM CELL TRANSPLANTATION; TUBERCULIN TEST; TUBERCULOSIS; VIRUS LOAD; AGED; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CROSS-SECTIONAL STUDY; IMMUNOLOGY; LATENT TUBERCULOSIS; MIDDLE AGED;

ADULT; AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON-GAMMA RELEASE TESTS; KIDNEY FAILURE, CHRONIC; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TUBERCULIN TEST;

EID: 84911863522     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201405-0967OC     Document Type: Article

References (44)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128.
2. Erkens CG, Kamphorst M, Abubakar I, Bothamley GH, Chemtob D, Haas W, Migliori GB, Rieder HL, Zellweger JP, Lange C. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010;36:925-949.
3. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, Bossink A, Magdorf K, Hölscher C, Kampmann B, et al.; C. Lange; TBNET. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009;33: 956-973.
4. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, Lange C, Losi M, Markova R, Migliori GB, et al . Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011;37:88-99.
5. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-564.
6. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, Fielding K, Wilkinson RJ, Pai M. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:45-55.
7. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010;59:1-25.
8. Sester M, Bumbacea D, Duarte R, Lange C. Tuberculosis in the immunocompromised host. Eur Respir Monogr 2012;58:230-241.
9. Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 2011;364:1441-1448.
10. Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007;175:737-742.
11. Leidl L, Mayanja-Kizza H, Sotgiu G, Baseke J, Ernst M, Hirsch C, Goletti D, Toossi Z, Lange C. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. Eur Respir J 2010;35:619-626.
12. Triverio PA, Bridevaux PO, Roux-Lombard P, Niksic L, Rochat T, Martin PY, Saudan P, Janssens JP. Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients. Nephrol Dial Transplant 2009;24:1952-1956.
13. Hadaya K, Bridevaux PO, Roux-Lombard P, Delort A, Saudan P, Martin PY, Janssens JP. Contribution of interferon-γ release assays (IGRAs) to the diagnosis of latent tuberculosis infection after renal transplantation. Transplantation 2013;95:1485-1490.
14. Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, Tortoli E, Mantella A, Benucci M, Girardi E, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009;33:586-593.
15. Kim SH, Lee SO, Park JB, Park IA, Park SJ, Yun SC, Jung JH, Kim YH, Kim SC, Choi SH, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant 2011;11:1927-1935.
16. Manuel O, Humar A, Preiksaitis J, Doucette K, Shokoples S, Peleg AY, Cobos I, Kumar D. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007;7:2797-2801.
17. Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, Aichelburg AC, Stingl G, Makristathis A, Kohrgruber N. Detection and prediction of active tuberculosis disease by a wholeblood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009;48:954-962.
18. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 2006;7:56.
19. Kim YJ, Kim SI, Kim YR, Wie SH, Park YJ, Kang MW. Predictive value of interferon-γ ELISPOT assay in HIV 1-infected patients in an intermediate tuberculosis-endemic area. AIDS Res Hum Retroviruses 2012;28:1038-1043.
20. Mantoux C. L'intradermo-reaction de la tuberculine et son interpretation clinique. Presse Med 1910;2:10-13.
21. Centers for Disease Control (CDC). Revision of the CDC surveillance case definition for acquired immunode ficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep 1987;36:1S-15S.
22. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-960.
23. Cochran WG. The comparison of percentages in matched samples. Biometrika 1950;37:256-266.
24. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
25. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer H; Swiss HIV Cohort Study. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007;44:94-102.
26. Aabye MG, Ravn P, PrayGod G, Jeremiah K, Mugomela A, Jepsen M, Faurholt D, Range N, Friis H, Changalucha J, et al. The impact of HIV infection and CD4 cell count on the performance of an interferon gamma release assay in patients with pulmonary tuberculosis. PLoS ONE 2009;4:e4220.
27. Sester U, Wilkens H, van Bentum K, Singh M, Sybrecht GW, Schäfers HJ, Sester M. Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs. Eur Respir J 2009;34:702-710.
28. Bumbacea D, Arend SM, Eyuboglu F, Fishman JA, Goletti D, Ison MG, Jones CE, Kampmann B, Kotton CN, Lange C, et al . The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J 2012;40:990-1013.
29. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, Perich R, Sanchez-Torres A, Pastor C, Sanchez-Schwartz C, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008;35:776-781.
30. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay. Ann Rheum Dis 2012;71:231-237.
31. Inanc N, Aydin SZ, Karakurt S, Atagunduz P, Yavuz S, Direskeneli H. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2009;36:2675-2681.
32. Greenberg JD, Reddy SM, Schloss SG, Kurucz OS, Bartlett SJ, Abramson SB, Bingham CO III. Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. J Rheumatol 2008;35:770-775.
33. Passalent L, Khan K, Richardson R, Wang J, Dedier H, Gardam M. Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel. Clin J Am Soc Nephrol 2007;2:68-73.
34. Winthrop KL, Nyendak M, Calvet H, Oh P, Lo M, Swarbrick G, Johnson C, Lewinsohn DA, Lewinsohn DM, Mazurek GH. Interferon-gamma release assays for diagnosing Mycobacterium tuberculosis infection in renal dialysis patients. Clin J Am Soc Nephrol 2008;3:1357-1363.
35. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for predicting progression from latent TB infection to disease state: a meta-analysis. Chest 2012;142:63-75.
36. Chee CB, Sester M, Zhang W, Lange C. Diagnosis and treatment of latent infection with Mycobacterium tuberculosis. Respirology 2013;18:205-216.
37. Soborg C, Ruhwald M, Andersen PH, Ravn P. 6-year follow-up of 522 HIV-positive individuals screened for Mycobacterium tuberculosis infection in Denmark. Eur Respir J 2014;44:540-543.
38. Jung YJ, Lyu J, Yoo B, Lee CK, Kim YG, Yang SK, Byeon JS, Kim KJ, Ye BD, Lee KH, et al. Combined use of a TST and the T-SPOT.TB assay for latent tuberculosis infection diagnosis before anti-TNF-αtreatment. Int J Tuberc Lung Dis 2012;16:1300-1306.
39. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005;19:2109-2116.
40. Karo B, Haas W, Kollan C, Gunsenheimer-Bartmeyer B, Hamouda O, Fiebig L; German ClinSurv HIV Study Group. Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors. BMC Infect Dis 2014;14:148.
41. Mancuso JD, Mazurek GH, Tribble D, Olsen C, Aronson NE, Geiter L, Goodwin D, Keep LW. Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med 2012;185:427-434.
42. European Centre for Disease Prevention and Control. Use of interferon-gamma release assays in support of TB diagnosis. Stockholm: ECDC; 2011.
43. Hermans SM, Manabe YC, Kiragga AN, Hoepelman AI, Lange JM, van Leth F. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting. Antivir Ther 2013;18:615-622.
44. Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis 1974;110:572-580.